|Bid||186.17 x 900|
|Ask||188.42 x 900|
|Day's range||184.78 - 188.54|
|52-week range||184.78 - 280.99|
|Beta (5Y monthly)||0.63|
|PE ratio (TTM)||24.83|
|Earnings date||27 Oct 2021 - 01 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||258.59|
Investors are optimistic about QIAGEN (QGEN) owing to impressive sales of diagnostic solutions and strong international growth.
New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups should drive sales of Vertex's (VRTX) cystic fibrosis drug, Trikafta sales higher.
Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.